FDA Safety Flag
The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.
Evidence visual
Retatrutide evidence and risk matrix
advanced researcher fit
Evidence
Tier C
Risk
med high
Regulatory
investigational
WADA
unknown
FDA
flagged
Route
subcutaneous
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
Retatrutide is an investigational multi-agonist metabolic peptide studied for obesity and metabolic disease. Early trial readouts suggest very large weight-loss potential, but published human evidence is still limited compared with approved incretin drugs. It is not approved, and FDA has taken a hard line against compounding unapproved agents in this class.
Decision path
Where Retatrutide fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Retatrutide belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Multi-receptor incretin agonism intended to amplify appetite suppression, insulin signaling, and energy-balance effects beyond GLP-1 alone.
subcutaneous
Early human studies use multi-mg weekly subcutaneous dosing; no approved regimen exists.
Preliminary human data suggest strong body-weight reduction and metabolic benefit, but the evidence base remains early-stage.
Expected to follow other incretin agents, with early appetite effects and larger changes over months.
Experimental compound; avoid outside regulated research or clinician-supervised contexts.
Likely significant GI intolerance profile with limited long-term safety clarity. Broader risk remains uncertain due to limited human exposure.
Assume class-like overlap with GLP-1 and GIP therapies; avoid layering with other incretin agents.
Cost at a glance
Typical cycle cost
$150.00
Estimated monthly
$150.00
Protocol style
Insufficient evidence
Insufficient evidence
Estimate confidence
High confidence
Assumes roughly 8 mg–20 mg per cycle, using 2 tracked affiliated listings.
Trial windows exist, but there is not yet a stable real-world cycle standard outside research.
Known Interactions
Approved GLP-1 therapy should not be layered with an investigational multi-incretin agent.
Two high-potency incretin agonists compound GI and glucose-management risk.
Do not layer a daily GLP-1 agonist with an investigational triple-agonist compound.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Retatrutide.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.